In AdCN103, the 24 bp deletion of E1A is combined with a modified hTERT promoter [29] and in SynOV1.1 (Ad5-Delta-24-RGD-hGMCSF) with an enhanced cancer-specific alpha-fetoprotein (AFP) promoter. Here, AFP is linked to cancer.